Oncology / Haematology

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Trial Name: THOR

PI: Dr Emma Beardsley

Who can take part:

• Patients with Histologic demonstration of transitional cell carcinoma of the urothelium.
• Patients with Metastatic or surgically unresectable urothelial cancer
• Patients must meet appropriate molecular eligibility criteria as determined by a Central Laboratory – Tumors must have at least 1 of the following translocations: FGFR2-BICC1, FGFR2-CASP7, FGFR3-TACC3, FGFR3-BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.

Exclusion criteria:

• Patients with symptomatic central nervous system metastases.
• Received prior FGFR inhibitor treatment.
• Patients with a history of uncontrolled cardiovascular disease

For further information please contact Judi Clarke – 03 9784 8301

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4